


## Lenalidomide-PEG1-azide

<b>Cat. No.:</b>	HY-133139		
<b>CAS No.:</b>	2185795-67-7		
<b>Molecular Formula:</b>	C <sub>17</sub> H <sub>18</sub> N <sub>6</sub> O <sub>5</sub>		
<b>Molecular Weight:</b>	386.36		
<b>Target:</b>	E3 Ligase Ligand-Linker Conjugates		
<b>Pathway:</b>	PROTAC		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (258.83 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	2.5883 mL	12.9413 mL	25.8826 mL
5 mM	0.5177 mL	2.5883 mL	5.1765 mL
10 mM	0.2588 mL	1.2941 mL	2.5883 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Lenalidomide-PEG1-azide is a E3 ligase ligand-linker conjugate. Lenalidomide-PEG1-azide incorporates the Lenalidomide based cereblon ligand and a linker. Lenalidomide-PEG1-azide can be used to design a PROTAC BRD4 Degradator-2 (HY-133136)<sup>[1]</sup>. Lenalidomide-PEG1-azide is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAC) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.

### REFERENCES

[1]. Zhang F, et al. Discovery of a new class of PROTAC BRD4 degraders based on a dihydroquinazolinone derivative and lenalidomide/pomalidomide. *Bioorg Med Chem.* 2020 Jan 1;28(1):115228.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA